Lenalidomide, bortezomib, and dexamethasone (RVD) regimen (Table 1) has been studied in multiple myeloma as induction therapy regardless of transplantation eligibility, consolidation therapy following transplantation or another dexamethasone-based regimen, and salvage therapy for relapsed or refractory cases. 1 – 8 Current guidelines ...

Grading right ventricular dysfunction (RVD) in patients with left ventricular (LV) disease has earned little attention. In the present study, we established an echocardiographic RVD score and investigated how increments of the score correspond to RVD at right heart catheterization.

RVd or VRd is given to alleviate myeloma symptoms and slow the progression of multiple myeloma, not to cure this disease. After treatment, patients who respond to RVd typically are either monitored, continue on to maintenance therapy, or proceed to bone marrow transplant.

2020年11月5日 · Lenalidomide, bortezomib, and dexamethasone (RVD) is a standard first-line regimen for patients with newly diagnosed multiple myeloma and is associated with high response rates and improvement in progression-free survival and overall survival compared to traditional chemotherapy regimens.

2011年11月18日 · The 28 day schedule of RVD is an efficacious, convenient, and well tolerated treatment regimen for patients with newly diagnosed symptomatic MM. The subcutaneous administration of bortezomib on this 28 day schedule may allow even further reductions in toxicity without sacrificing efficacy.

Lenalidomide, bortezomib and dexamethasone (RVD, sometimes used interchangeably with the acronym VRD, although originally this was used to describe a different regimen detailed below) is the preferred induction regimen for most patients with …

2021年6月2日 · Understanding the prognostic impact of right ventricular dysfunction (RVD) in cardiogenic shock (CS) is a key step toward rational diagnostic and treatment algorithms and improved outcomes.

2025年1月31日 · Right ventricular dysfunction usually results from either pressure overload, volume overload, or a combination. It occurs in a number of clinical scenarios, including: It can manifest as right heart strain. Sustained right ventricular dilatation and hypertrophy can frequently progress to right ventricular failure.

RVD is associated with poor outcomes in CS, with key differences across etiology and shock severity. Further studies are needed to assess the usefulness of RVD assessment in guiding therapy.

The Understanding the VRd Regimen booklet discusses a combination therapy for treating newly diagnosed myeloma that consists of three drugs: Velcade® (generic drug name bortezomib), Revlimid® (generic name lenalidomide), and dexamethasone (which is a generic name; there are many branded products).